Pfizer has gained European rights to Auxilium Pharmaceuticals’ Xiaflex™ (clostridial collagenase for injection) – a novel, first-in-class, late-stage biologic, for the treatment of Dupuytren's contracture and Peyronie's disease. There is a growing trend for Big Pharma to build up their specialty care product portfolio, illustrated by the multiple offers that Auxilium says it received for Xiaflex.